Tag: Pharmaceuticals

William Michael, Aidan Synnott, Jun 27, 2012 For over a decade, the Federal Trade Commission has sought, with little success, to end "reverse settlement" payments...

Herbert Hovenkamp, Dec 13, 2011 In Lundbeck the Eighth Circuit affirmed a district court's decision approving a merger of the only two drugs authorized to...

Dec 16, 2010 The year is 2025. For the past two decades, brand-name drug companies have settled infringement lawsuits with generic firms by paying them...

Sean-Paul Brankin, Sep 30, 2010 On July 1, 2010, the General Court issued its long awaited judgment in AstraZeneca v Commission, almost five years after...

Patrick Harrison, Kristina Nordlander, Sep 30, 2010 Five years and two weeks is a long time to wait for a judgment on appeal. For many,...

Kent Bernard, Sep 30, 2010 By its decision of July 1, 2010 in AstraZeneca the General Court upheld the decision of the European Commission that...

Marc van der Waude, Marc van der Waude, Nov 01, 2009 The purpose of this contribution is to explore the status types that settlements and...

This article is part of a Chronicle. See more from this Chronicle Charlene Jones, Aidan Synnott, Nov 25, 2009 In October 2009, the United States Court...

Anne Layne-Farrar, Nov 01, 2009 This article begins by laying out a simple framework that makes obvious the incentives at play in generic drug entry,...

Michael Kades, Nov 01, 2009 Arguably, the most important debate in antitrust jurisprudence involves pay-for-delay patent settlements in which the brand company pays the generic...